{"created":"2023-05-15T14:58:45.015162+00:00","id":84,"links":{},"metadata":{"_buckets":{"deposit":"e0a7afc5-dfc1-4917-85fa-b60b5c5ed909"},"_deposit":{"created_by":10,"id":"84","owners":[10],"pid":{"revision_id":0,"type":"depid","value":"84"},"status":"published"},"_oai":{"id":"oai:meiji-u.repo.nii.ac.jp:00000084","sets":["2:11"]},"author_link":["198"],"item_10004_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2010-02-02","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"2","bibliographicPageEnd":"9","bibliographicPageStart":"1","bibliographic_titles":[{"bibliographic_title":"明治国際医療大学誌"},{"bibliographic_title":"The Bulletin of Meiji University of Integrative Medicine","bibliographic_titleLang":"en"}]}]},"item_10004_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"関節リウマチの治療は,生物学的製剤の導入により,寛解を目指す時代を迎え,パラダイムシフトとよばれている.現在では,関節疼痛や腫脹などの症状改善のみならず,X線学的に関節破壊の進行防止が治療目的になっている.早期に確定診断をおこない,抗リウマチ剤による早期治療が可能なように,このたび22年ぶりにRA診断基準が改訂された(2009ACR/EULAR基準).治療法としてはメトトレキサート(MTX)が治療の基準薬として推奨され,3ヵ月以上使用しても効果がない場合は,生物学的製剤の使用が奨励されている.現在日本では生物学的製剤として,腫瘍壊死因子(TNF)阻害薬3種(インフリキシマブ,エタネルセプト,アダリムマブ)とインターロイキン(IL)-6阻害薬1種(トシリズマブ)が承認・販売されている.生物学的製剤と,MTX併用により寛解導入,関節破壊進行の抑制,さらに生命予後の改善が見込まれる.ただし,重篤な副作用として肺炎等の感染症や他の合併症に注意が必要である.今後の研究により,より有効で安全な治療法ならびにRAの原因解明が強く望まれる.(著者抄録)","subitem_description_type":"Abstract"}]},"item_10004_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1884-1414","subitem_source_identifier_type":"ISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"糸井, 恵"},{"creatorName":"イトイ, メグミ","creatorNameLang":"ja-Kana"},{"creatorName":"Itoi, Megumi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"198","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2022-02-25"}],"displaytype":"detail","filename":"01_itoi.pdf","filesize":[{"value":"2.6 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"01_itoi","url":"https://meiji-u.repo.nii.ac.jp/record/84/files/01_itoi.pdf"},"version_id":"158cac95-b5d4-4e6b-8630-9b7eaf111ce3"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"関節リウマチ","subitem_subject_scheme":"Other"},{"subitem_subject":"RA 診断基準 2009","subitem_subject_scheme":"Other"},{"subitem_subject":"生物学的 製剤","subitem_subject_scheme":"Other"},{"subitem_subject":"TNF 阻害薬","subitem_subject_scheme":"Other"},{"subitem_subject":"寛解","subitem_subject_scheme":"Other"},{"subitem_subject":"rheumatoid arthritis","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"RA criteria 2009","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"biologics","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"anti-TNF drugs","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"remission","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"関節リウマチの治療法の進歩　生物学的製剤を中心に","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"関節リウマチの治療法の進歩　生物学的製剤を中心に"},{"subitem_title":"Current therapeutic strategies for rheumatoid arthritis","subitem_title_language":"en"}]},"item_type_id":"10004","owner":"10","path":["11"],"pubdate":{"attribute_name":"公開日","attribute_value":"2022-02-25"},"publish_date":"2022-02-25","publish_status":"0","recid":"84","relation_version_is_last":true,"title":["関節リウマチの治療法の進歩　生物学的製剤を中心に"],"weko_creator_id":"10","weko_shared_id":-1},"updated":"2023-05-15T15:50:51.721543+00:00"}